Axsome Logo.png
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022 06:30 ET | Axsome Therapeutics, Inc.
Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint) Statistically significant patient-reported improvement in...
Axsome Logo.png
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research
September 07, 2022 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
June 28, 2022 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Physician Growth Partners advises Orthopaedic Specialists of Austin in transaction with Growth Ortho
June 22, 2022 10:30 ET | Physician Growth Partners
CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Physician Growth Partners ("PGP") is pleased to have advised Orthopaedic Specialists of Austin ("OSA" or the "Company"), in its recent transaction with...
Axsome Logo.png
Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
June 22, 2022 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
March 28, 2022 06:00 ET | Axsome Therapeutics, Inc.
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
March 23, 2022 08:00 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
respirerx.jpg
Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward
March 07, 2022 08:00 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO 
November 04, 2021 08:45 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), (“RespireRx” or the “Company”) a leader in the discovery and development of innovative and...
Luminate.png
Luminate NY Announces The Optical Society to Sponsor Finals 2021 Competition
August 26, 2021 09:00 ET | Luminate
ROCHESTER, N.Y., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Luminate NY, the world's largest accelerator for startups with optics, photonics, and imaging(OPI) enabled applications, announced today that The...